British drugmaker AstraZeneca said on Saturday (Feb.
6) its vaccine developed with the University of Oxford appeared to offer only limited protection against mild disease caused by the South African variant of COVID-19, based on early data from a trial.
Edward Baran reports.
AstraZeneca
University of Oxford
COVID-19
Edward Baran
British Prime Minister Boris Johnson in an interview with CBS on Sunday said he has "great confidence" in the AstraZeneca and..
There is still some hope that the AstraZeneca and Oxford COVID-19 vaccine will prevent severe disease from the South African..
